ROMISET 500MCG INJECTION is used for chronic immune thrombocytopenic purpura (ITP) patients one year of age and older who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. It contains Romiplostim which belongs to the group of medicines called Thrombopoietin receptor agonists which works by stimulating the bone marrow (part of the bone which makes blood cells) to produce more platelets. This should help to manage bruising and bleeding associated with ITP.

ROMISET 500MCG INJECTION should be used with caution in patients with thromboembolism including but not limited to inherited or acquired risk factors, advanced age, prolonged periods of immobilization, malignancies, have any clinical conditions associated with thrombocytopenia or have any renal impairment. ROMISET 500MCG INJECTION is not recommended for use in pregnant women and patients having severe to moderate liver impairment.

The safety and efficacy of ROMISET 500MCG INJECTION in children under the age of one year has not been established. The most common side effects of receiving ROMISET 500MCG INJECTION are fatigue, oedema peripheral, influenza like illness, pain, chills, injection site reaction. Consult your doctor if any of the above side effects worsen or persist for a long time.